Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Tatsuki IkomaMototsugu ShimokawaToshihiko MatsumotoShogen BokuTomoyo YasudaNobuhiro ShibataYusuke KuriokaMasahiro TakataniTetsuji NobuhisaTsutomu NamikawaHiroyuki KitagawaKazuhiro HanazakiKeitaro DoiTakanobu ShimadaTakehiko TsumuraHiroyuki MarusawaSeichiro KanayaShuko MoritaTetsurou InokumaHiroki NagaiHisateru YasuiHironaga SatakePublished in: Cancer immunology, immunotherapy : CII (2022)
Inflammatory prognostic factors were useful in predicting prognosis for ESCC patients pretreated with nivolumab, especially for those with CAR < 0.62, suggesting that CAR adequately reflects prognosis.